Peripheral Neuropathies in Infectious Diseases

Abstract

Peripheral nerve disorders may be the presenting manifestation of a systemic infection, and early recognition of these syndromes is essential for prompt diagnosis and treatment. Mechanisms associated with infectious disorders of the peripheral nerve are often complex and multiple, with secondary inflammation, direct infectious invasion of nerves, and toxicities of antimicrobial medications playing a role. Here, we provide a complete review of the most common infectious pathogens that can affect the peripheral nerves.

Keywords

peripheral nerve - infection - HIV

^* These authors contributed equally to this work.

• References

• 1 Morgello S, Estanislao L, Simpson D. , et al; Manhattan HIV Brain Bank. HIV-associated distal sensory polyneuropathy in the era of highly active antiretroviral therapy: the Manhattan HIV Brain Bank. Arch Neurol 2004; 61 (04) 546-551
• 2 Schifitto G, McDermott MP, McArthur JC. , et al; Dana Consortium on the Therapy of HIV Dementia and Related Cognitive Disorders. Incidence of and risk factors for HIV-associated distal sensory polyneuropathy. Neurology 2002; 58 (12) 1764-1768
• 3 Geraci AP, Simpson DM. Neurological manifestations of HIV-1 infection in the HAART era. Compr Ther 2001; 27 (03) 232-241
• 4 Marra CM, Boutin P, Collier AC. Screening for distal sensory peripheral neuropathy in HIV-infected persons in research and clinical settings. Neurology 1998; 51 (06) 1678-1681
• 5 Cornblath DR, Chaudhry V, Carter K. , et al. Total neuropathy score: validation and reliability study. Neurology 1999; 53 (08) 1660-1664
• 6 Moyle GJ, Sadler M. Peripheral neuropathy with nucleoside antiretrovirals: risk factors, incidence and management. Drug Saf 1998; 19 (06) 481-494
• 7 Lehmann HC, Chen W, Borzan J, Mankowski JL, Höke A. Mitochondrial dysfunction in distal axons contributes to human immunodeficiency virus sensory neuropathy. Ann Neurol 2011; 69 (01) 100-110
• 8 Simpson DM, Brown S, Tobias J. ; NGX-4010 C107 Study Group. Controlled trial of high-concentration capsaicin patch for treatment of painful HIV neuropathy. Neurology 2008; 70 (24) 2305-2313
• 9 Simpson DM, Schifitto G, Clifford DB. , et al; 1066 HIV Neuropathy Study Group. Pregabalin for painful HIV neuropathy: a randomized, double-blind, placebo-controlled trial. Neurology 2010; 74 (05) 413-420
• 10 Simpson DM, Rice ASC, Emir B. , et al. A randomized, double-blind, placebo-controlled trial and open-label extension study to evaluate the efficacy and safety of pregabalin in the treatment of neuropathic pain associated with human immunodeficiency virus neuropathy. Pain 2014; 155 (10) 1943-1954
• 11 Brannagan III TH, Zhou Y. HIV-associated Guillain-Barré syndrome. J Neurol Sci 2003; 208 (1-2): 39-42
• 12 Shepherd SJ, Black H, Thomson EC, Gunson RN. HIV positive patient with GBS-like syndrome. JMM Case Rep 2017; 4 (08) e005107
• 13 Mochan A, Anderson D, Modi G. CIDP in a HIV endemic population: a prospective case series from Johannesburg, South Africa. J Neurol Sci 2016; 363 (363) 39-42
• 14 Shah SS, Rodriguez T, McGowan JP. Miller Fisher variant of Guillain-Barré syndrome associated with lactic acidosis and stavudine therapy. Clin Infect Dis 2003; 36 (10) e131-e133
• 15 Hadden RD, Cornblath DR, Hughes RA. , et al; Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Ann Neurol 1998; 44 (05) 780-788
• 16 Marshall DW, Brey RL, Cahill WT, Houk RW, Zajac RA, Boswell RN. Spectrum of cerebrospinal fluid findings in various stages of human immunodeficiency virus infection. Arch Neurol 1988; 45 (09) 954-958
• 17 Gisslén M, Chiodi F, Fuchs D. , et al. Markers of immune stimulation in the cerebrospinal fluid during HIV infection: a longitudinal study. Scand J Infect Dis 1994; 26 (05) 523-533
• 18 Rosca EC, Rosca O, Simu M. Intravenous immunoglobulin treatment in a HIV-1 positive patient with Guillain-Barré syndrome. Int Immunopharmacol 2015; 29 (02) 964-965
• 19 Kume K, Ikeda K, Kamada M, Touge T, Deguchi K, Masaki T. Successful treatment of HIV-associated chronic inflammatory demyelinating polyneuropathy by early initiation of highly active anti-retroviral therapy. Rinsho Shinkeigaku 2013; 53 (05) 362-366
• 20 van der Meché FG, Schmitz PI. ; Dutch Guillain-Barré Study Group. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. N Engl J Med 1992; 326 (17) 1123-1129
• 21 Sugimoto H, Konno S, Takamiya K, Nemoto H, Wakata N, Kurihara T. [A case of primary HIV infection presenting as mononeuritis multiplex]. Rinsho Shinkeigaku 2006; 46 (08) 561-563
• 22 Stricker RB, Sanders KA, Owen WF, Kiprov DD, Miller RG. Mononeuritis multiplex associated with cryoglobulinemia in HIV infection. Neurology 1992; 42 (11) 2103-2105
• 23 Lyons J, Venna N, Cho TA. Atypical nervous system manifestations of HIV. Semin Neurol 2011; 31 (03) 254-265
• 24 Bélec L, Gherardi R, Georges AJ. , et al. Peripheral facial paralysis and HIV infection: report of four African cases and review of the literature. J Neurol 1989; 236 (07) 411-414
• 25 Amayo EO, Kwasa TO. HIV and acute peripheral facial nerve palsy. East Afr Med J 1991; 68 (12) 948-951
• 26 Sullivan FM, Swan IRC, Donnan PT. , et al. Early treatment with prednisolone or acyclovir in Bell's palsy. N Engl J Med 2007; 357 (16) 1598-1607
• 27 Keane JR. Bilateral seventh nerve palsy: analysis of 43 cases and review of the literature. Neurology 1994; 44 (07) 1198-1202
• 28 Levay P, Botes ME. Diffuse infiltrative lymphocytosis syndrome (DILS). S Afr Fam Pract 2008; 50 (02) 42-44
• 29 Ghrenassia E, Martis N, Boyer J, Burel-Vandenbos F, Mekinian A, Coppo P. The diffuse infiltrative lymphocytosis syndrome (DILS). A comprehensive review. J Autoimmun 2015; 59: 19-25
• 30 Golbus JR, Gallagher G, Blackburn G, Cinti S. Polyneuropathy associated with the diffuse infiltrative lymphocytosis syndrome. J Int Assoc Physicians AIDS Care (Chic) 2012; 11 (04) 223-226
• 31 Wasley A, Fiore A, Bell BP. Hepatitis A in the era of vaccination. Epidemiol Rev 2006; 28: 101-111
• 32 Marés-Segura R, Solá-Lamoglia R, Soler-Singla L, Pou-Serradell A. Guillain-Barré syndrome associated with hepatitis A. Ann Neurol 1986; 19 (01) 100
• 33 Dunk A, Jenkins WJ, Sherlock S. Guillain-Barré syndrome associated with hepatitis A in a male homosexual. Br J Vener Dis 1982; 58 (04) 269-270
• 34 Tabor E. Guillain-Barré syndrome and other neurologic syndromes in hepatitis A, B, and non-A, non-B. J Med Virol 1987; 21 (03) 207-216
• 35 Pelletier G, Elghozi D, Trépo C, Laverdant C, Benhamou JP. Mononeuritis in acute viral hepatitis. Digestion 1985; 32 (01) 53-56
• 36 Lai CL, Ratziu V, Yuen MF, Poynard T. Viral hepatitis B. Lancet 2003; 362 (9401): 2089-2094
• 37 Guillevin L, Lhote F, Cohen P. , et al. Polyarteritis nodosa related to hepatitis b virus: a prospective study with long-term observation of 41 patients. Medicine (Baltimore) 1995; 74 (05) 238-253
• 38 Jacobs BC, Rothbarth PH, van der Meché FGA. , et al. The spectrum of antecedent infections in Guillain-Barré syndrome: a case-control study. Neurology 1998; 51 (04) 1110-1115
• 39 Mehndiratta M, Pandey S, Nayak R, Saran RK. Acute onset distal symmetrical vasculitic polyneuropathy associated with acute hepatitis B. J Clin Neurosci 2013; 20 (02) 331-332
• 40 Souayah N, Nasar A, Suri MF, Qureshi AI. Guillain-Barr syndrome after vaccination in United States: data from the centers for disease control and prevention/food and drug administration vaccine adverse event reporting system (1990–2005). J Clin Neuromuscul Dis 2009; 11 (01) 1-6
• 41 de Carvalho JF, Pereira RM, Shoenfeld Y. Systemic polyarteritis nodosa following hepatitis B vaccination. Eur J Intern Med 2008; 19 (08) 575-578
• 42 De Keyser F, Naeyaert JM, Hindryckx P. , et al. Immune-mediated pathology following hepatitis B vaccination. Two cases of polyarteritis nodosa and one case of pityriasis rosea-like drug eruption. Clin Exp Rheumatol 2000; 18 (01) 81-85
• 43 Ventura F, Antunes H, Brito C, Pardal F, Pereira T, Vieira AP. Cutaneous polyarteritis nodosa in a child following hepatitis B vaccination. Eur J Dermatol 2009; 19 (04) 400-401
• 44 Gumber SC, Chopra S. Hepatitis C: a multifaceted disease. Review of extrahepatic manifestations. Ann Intern Med 1995; 123 (08) 615-620
• 45 Cacoub P, Gragnani L, Comarmond C, Zignego AL. Extrahepatic manifestations of chronic hepatitis C virus infection. Dig Liver Dis 2014; 46 (Suppl. 05) S165-S173
• 46 Mariotto S, Ferrari S, Monaco S. HCV-related central and peripheral nervous system demyelinating disorders. Inflamm Allergy Drug Targets 2014; 13 (05) 299-304
• 47 Nemni R, Sanvito L, Quattrini A, Santuccio G, Camerlingo M, Canal N. Peripheral neuropathy in hepatitis C virus infection with and without cryoglobulinaemia. J Neurol Neurosurg Psychiatry 2003; 74 (09) 1267-1271
• 48 Lidove O, Cacoub P, Maisonobe T. , et al. Hepatitis C virus infection with peripheral neuropathy is not always associated with cryoglobulinaemia. Ann Rheum Dis 2001; 60 (03) 290-292
• 49 Cacoub P, Comarmond C, Domont F, Savey L, Saadoun D. Cryoglobulinemia Vasculitis. Am J Med 2015; 128 (09) 950-955
• 50 Apartis E, Léger JM, Musset L. , et al. Peripheral neuropathy associated with essential mixed cryoglobulinaemia: a role for hepatitis C virus infection?. J Neurol Neurosurg Psychiatry 1996; 60 (06) 661-666
• 51 McKee DH, Young AC, Alonso-Dominguez A. , et al. Neurologic complications associated with hepatitis C virus infection [5] (multiple letters). Neurology 2000; 55 (03) 459
• 52 David WS, Peine C, Schlesinger P, Smith SA. Nonsystemic vasculitic mononeuropathy multiplex, cryoglobulinemia, and hepatitis C. Muscle Nerve 1996; 19 (12) 1596-1602
• 53 Cacoub P, Lidove O, Maisonobe T. , et al. Interferon-alpha and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis. Arthritis Rheum 2002; 46 (12) 3317-3326
• 54 Cacoub P, Saadoun D, Limal N, Sene D, Lidove O, Piette JC. PEGylated interferon alfa-2b and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis. Arthritis Rheum 2005; 52 (03) 911-915
• 55 Naarendorp M, Kallemuchikkal U, Nuovo GJ, Gorevic PD. Long term efficacy of interferon-α for extrahepatic disease associated with hepatitis C virus infection. J Rheumatol 2001; 28 (11) 2466-2473
• 56 Cacoub P, Si Ahmed SN, Ferfar Y. , et al. Long-term efficacy of interferon-free antiviral treatment regimens in patients with hepatitis C virus-associated cryoglobulinemia vasculitis. Clin Gastroenterol Hepatol 2019; 17 (03) 518-526
• 57 Mazzaro C, Dal Maso L, Quartuccio L. , et al. Long-term effects of the new direct antiviral agents (DAAs) therapy for HCV-related mixed cryoglobulinaemia without renal involvement: a multicentre open-label study. Clin Exp Rheumatol 2018; 36 Suppl 111 (02) 107-114
• 58 Sise ME, Bloom AK, Wisocky J. , et al. Treatment of hepatitis C virus-associated mixed cryoglobulinemia with direct-acting antiviral agents. Hepatology 2016; 63 (02) 408-417
• 59 Zaja F, De Vita S, Mazzaro C. , et al. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 2003; 101 (10) 3827-3834
• 60 Ferri C, Cacoub P, Mazzaro C. , et al. Treatment with rituximab in patients with mixed cryoglobulinemia syndrome: results of multicenter cohort study and review of the literature. Autoimmun Rev 2011; 11 (01) 48-55
• 61 Sneller MC, Hu Z, Langford CA. A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus-associated cryoglobulinemic vasculitis. Arthritis Rheum 2012; 64 (03) 835-842
• 62 Lamprecht P, Lerin-Lozano C, Merz H. , et al. Rituximab induces remission in refractory HCV associated cryoglobulinaemic vasculitis. Ann Rheum Dis 2003; 62 (12) 1230-1233
• 63 Moretti R, Caruso P, Dal Ben M, Gazzin S, Tiribelli C. Hepatitis C-related cryoglobulinemic neuropathy: potential role of oxcarbazepine for pain control. BMC Gastroenterol 2018; 18 (01) 19
• 64 Kamar N, Bendall R, Legrand-Abravanel F. , et al. Hepatitis E. Lancet 2012; 379 (9835): 2477-2488
• 65 Pérez-Gracia MT, Suay B, Mateos-Lindemann ML. Hepatitis E: an emerging disease. Infect Genet Evol 2014; 22: 40-59
• 66 Dartevel A, Colombe B, Bosseray A. , et al. Hepatitis E and neuralgic amyotrophy: Five cases and review of literature. J Clin Virol 2015; 69 (69) 156-164
• 67 Ellie E, Rozenberg F, Dousset V, Beylot-Barry M. Herpes simplex virus type 2 ascending myeloradiculitis: MRI findings and rapid diagnosis by the polymerase chain method. J Neurol Neurosurg Psychiatry 1994; 57 (07) 869-870
• 68 Eberhardt O, Küker W, Dichgans J, Weller M. HSV-2 sacral radiculitis (Elsberg syndrome). Neurology 2004; 63 (04) 758-759
• 69 Aurelius E, Forsgren M, Gille E, Sköldenberg B. Neurologic morbidity after herpes simplex virus type 2 meningitis: a retrospective study of 40 patients. Scand J Infect Dis 2002; 34 (04) 278-283
• 70 Cohen JI. Clinical practice: herpes zoster. N Engl J Med 2013; 369 (03) 255-263
• 71 Chodkiewicz HM, Cohen PR, Robinson FW, Rae ML. Ramsay Hunt syndrome revisited. Cutis 2013; 91 (04) 181-184
• 72 Sweeney CJ, Gilden DH. Ramsay Hunt syndrome. J Neurol Neurosurg Psychiatry 2001; 71 (02) 149-154
• 73 Hadley GR, Gayle JA, Ripoll J, Jones MR, Argoff CE, Kaye RJ, Kaye AD. Postherpetic neuralgia: a review. Curr Pain Headache Rep 2016; 20 (03) 17
• 74 Cheng J, Rosenquist RW. Herpes zoster and postherpetic neuralgia. In: Fundamentals of Pain Medicine. Cham, Switzerland: Spriger; 2018
• 75 Forbes HJ, Thomas SL, Smeeth L. , et al. A systematic review and meta-analysis of risk factors for postherpetic neuralgia. Pain 2016; 157 (01) 30-54
• 76 Murakami S, Mizobuchi M, Nakashiro Y, Doi T, Hato N, Yanagihara N. Bell palsy and herpes simplex virus: identification of viral DNA in endoneurial fluid and muscle. Ann Intern Med 1996; 124 (1, Pt 1): 27-30
• 77 Uscategui T, Dorée C, Chamberlain IJ, Burton MJ. Antiviral therapy for Ramsay Hunt syndrome (herpes zoster oticus with facial palsy) in adults. Cochrane Database Syst Rev 2008; (04) CD006851
• 78 Behar R, Wiley C, McCutchan JA. Cytomegalovirus polyradiculoneuropathy in acquired immune deficiency syndrome. Neurology 1987; 37 (04) 557-561
• 79 Orlikowski D, Porcher R, Sivadon-Tardy V. , et al. Guillain-Barré syndrome following primary cytomegalovirus infection: a prospective cohort study. Clin Infect Dis 2011; 52 (07) 837-844
• 80 Roullet E, Assuerus V, Gozlan J. , et al. Cytomegalovirus multifocal neuropathy in AIDS: analysis of 15 consecutive cases. Neurology 1994; 44 (11) 2174-2182
• 81 Kim YS, Hollander H. Polyradiculopathy due to cytomegalovirus: report of two cases in which improvement occurred after prolonged therapy and review of the literature. Clin Infect Dis 1993; 17 (01) 32-37
• 82 Brasil P, Sequeira PC, Freitas AD. , et al. Guillain-Barré syndrome associated with Zika virus infection. Lancet 2016; 387 (10026): 1482
• 83 Watrin L, Ghawché F, Larre P, Neau JP, Mathis S, Fournier E. . Guillain-Barré syndrome (42 cases) occurring during a Zika virus outbreak in French Polynesia. Medicine (Baltimore) 2016; 95 (14) e3257
• 84 Da Silva IR. Neurologic Complications Associated With the Zika Virus in Brazilian Adults. JAMA Neurol 2017; 74 (10) 1190-1198
• 85 Nascimento OJ, Da Silva IR. Guillain-Barre syndrome and Zika virus outbreaks. Curr Opin Neurol 2017; 30 (05) 500-507
• 86 Petersen LR, Brault AC, Nasci RS. West Nile virus: review of the literature. JAMA 2013; 310 (03) 308-315
• 87 Sejvar JJ, Haddad MB, Tierney BC. , et al. Neurologic manifestations and outcome of West Nile virus infection. JAMA 2003; 290 (04) 511-515
• 88 World Health Organization. WHO expert consultation on rabies. Second report. World Health Organ Tech Rep Ser 2013; (982) 1-139
• 89 Hemachudha T, Ugolini G, Wacharapluesadee S, Sungkarat W, Shuangshoti S, Laothamatas J. Human rabies: neuropathogenesis, diagnosis, and management. Lancet Neurol 2013; 12 (05) 498-513
• 90 Jackson AC. Current and future approaches to the therapy of human rabies. Antiviral Res 2013; 99 (01) 61-67
• 91 Global leprosy situation, 2012. Wkly Epidemiol Rec 2012; 87 (34) 317-328
• 92 Rodrigues LC, Lockwood DNj. Leprosy now: epidemiology, progress, challenges, and research gaps. Lancet Infect Dis 2011; 11 (06) 464-470
• 93 Sabin TD, Swift TR, Jacobson RR. Leprosy. In: Dyck PJ, Thomas PK. , eds. Peripheral Neuropathy. Philadelphia, PA: Saunders; 2005
• 94 Agrawal A, Pandit L, Dalal M, Shetty JP. Neurological manifestations of Hansen's disease and their management. Clin Neurol Neurosurg 2005; 107 (06) 445-454
• 95 Britton WJ, Lockwood DNJ. Leprosy. Lancet 2004; 363 (9416): 1209-1219
• 96 Hadfield TL, McEvoy P, Polotsky Y, Tzinserling VA, Yakovlev AA. The pathology of diphtheria. J Infect Dis 2000; 181 (Suppl. 01) S116-S120
• 97 Kole AK, Roy R, Kar SS, Chanda D. Outcomes of respiratory diphtheria in a tertiary referral infectious disease hospital. Indian J Med Sci 2010; 64 (08) 373-377
• 98 Piradov MA, Pirogov VN, Popova LM, Avdunina IA. Diphtheritic polyneuropathy: clinical analysis of severe forms. Arch Neurol 2001; 58 (09) 1438-1442
• 99 Howard Jr JF. Electrodiagnosis of disorders of neuromuscular transmission. Phys Med Rehabil Clin N Am 2013; 24 (01) 169-192
• 100 Zhang J-C, Sun L, Nie Q-H. Botulism, where are we now?. Clin Toxicol (Phila) 2010; 48 (09) 867-879
• 101 Hughes JM, Blumenthal JR, Merson MH, Lombard GL, Dowell Jr VR, Gangarosa EJ. Clinical features of types A and B food-borne botulism. Ann Intern Med 1981; 95 (04) 442-445
• 102 Chalk CH, Benstead TJ, Keezer M. Medical treatment for botulism. Cochrane Database Syst Rev 2014; (02) CD008123
• 103 Diaz JH. A 60-year meta-analysis of tick paralysis in the United States: a predictable, preventable, and often misdiagnosed poisoning. J Med Toxicol 2010; 6 (01) 15-21